ReviewCell & bioscience2023
Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.
Review in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- Nitric Oxide in the Intestinal Stem Cell Niche: A Spatial Model of Nitrosative Stress and Clonal Evolution in Colitis-Associated Colorectal Cancer.Digestive diseases and sciences · 2026Review
- TNF-α-responsive YAP1 promotes CCL20 expression in colorectal inflammation and cancer.Scientific reports · 2026Article
- Insights into the Relevance of the Interaction between Colorectal Cancer and Gut Microbiota-Derived Metabolites.Journal of cancer prevention · 2026Review
- Virome-Associated Hepatitis B Protein X Drives Epithelial-Mesenchymal Plasticity and Enhances Colorectal Carcinogenesis.Cellular and molecular gastroenterology and hepatology · 2026Article
- Potential role of PPARGC1A in linking ulcerative colitis to colorectal cancer: a novel prognostic biomarker and therapeutic target.Translational cancer research · 2026Article
- Integrin CD11b/CD18 reprograms macrophage polarization by suppressing ERK/STAT3 signaling to enhance antitumor immunity in colitis-associated colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- The Aging Microenvironment Shapes Angiogenic Remodeling in IBD-Associated Colorectal Carcinogenesis.Aging cell · 2026Review
- Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and fibrosis attenuation in ulcerative colitis.Journal of nanobiotechnology · 2026Article
- Gut microbiota and the colorectal cancer tumor microenvironment: From carcinogenic mechanisms to therapeutic opportunities.World journal of gastrointestinal oncology · 2026Review
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
- The gut-skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management.Frontiers in microbiology · 2026Review
- The microbiome in cancer.iMeta · 2025Review
- Utilization of AhR and GPR35 Receptor Ligands as Superfoods in Cancer Prevention for Individuals with IBD.International journal of molecular sciences · 2025Review
- The Microbiota-Diet-Immunity Axis in Cancer Care: From Prevention to Treatment Modulation and Survivorship.Nutrients · 2025Review
- Article
- Clinical Characteristics of Patients With Ulcerative Colitis and Small Intestinal Malignancy.Crohn's & colitis 360 · 2025Article
- The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential.Medical oncology (Northwood, London, England) · 2025Review
- VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies.Cancer metastasis reviews · 2025Review
- Genomic characterization of Escherichia coli with a polyketide synthase (pks) island isolated from ulcerative colitis patients.BMC genomics · 2025Article
- Neutrophils in inflammatory bowel disease: disease-promoting versus protective functions.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. One of the main causes of colorectal cancer is inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD). Intestinal epithelial cells (IECs), intestinal mesenchymal cells (IMCs), immune cells, and gut microbiota construct the main body of the colon and maintain colon homeostasis. In the development of colitis and colitis-associated carcinogenesis, the damage, disorder or excessive recruitment of different cells such as IECs, IMCs, immune cells and intestinal microbiota play different roles during these processes. This review aims to discuss the various roles of different cells and the crosstalk of these cells in transforming intestinal inflammation to cancer, which provides new therapeutic methods for chemotherapy, targeted therapy, immunotherapy and microbial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.